MedPath

Tracking Inflammatory Cells Using Superparamagnetic Particles of Iron Oxide (SPIO) and Magnetic Resonance Imaging (MRI)

Not Applicable
Completed
Conditions
Healthy
Interventions
Biological: Mantoux test
Drug: Administration of intra-dermal Endorem
Biological: Autologous Endorem-labelled mononuclear cells
Drug: Administration of Endorem
Registration Number
NCT01169935
Lead Sponsor
University of Edinburgh
Brief Summary

Treatment of a wide range of diseases using stem cells and other types of cell appears promising. Following administration of cells it is often not clear where exactly the cells have gone and how many of them have reached the target site. This has been one of the challenges of developing these treatment options further. We have developed a method of labelling human cells with a magnetic resonance imaging (MRI) "contrast agent" which contains tiny iron filings. Following intravenous administration it is possible to see where the iron-labelled cells have gone using MRI scanning. We would like to do is to demonstrate that these cells behave normally and migrate to a site of inflammation. We plan to induce an area of inflammation in the forearm of healthy volunteers using the Mantoux test (a test of immunity against tuberculosis) before giving the labelled cells intravenously. After the Mantoux test we will give these volunteers iron-labelled cells and do MRI scans of their forearm to determine whether these cells can be seen accumulating in the target site.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
12
Inclusion Criteria
  • Healthy male or female volunteers age 18 to 65 years
  • Previous vaccine for tuberculosis more than 5 years ago
Exclusion Criteria
  • pregnancy / breast feeding
  • Contra-indication to MRI scanning
  • Inability or refusal to give informed consent
  • Renal failure (eGFR <25mL/min) or hepatic dysfunction (Child's B or C)
  • HIV/hepatitis B/hepatitis C/HTLV/syphilis
  • Active malignant disease
  • Anaemia
  • Blood dyscrasia
  • High risk of allergy to protamine sulphate (fish allergy, infertile men, vasectomy)
  • Known history of tuberculosis infection.
  • History of prolonged residence (> 6 months) in a region or country with a high prevalence of tuberculosis.
  • Previous Mantoux reaction of 15mm of greater.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Mantoux, Venesection, Labelled cellsMantoux testMantoux test then MRI scanning before and after administration of iron-labelled cells obtained by venesection.
Mantoux, Venesection, Labelled cellsAutologous Endorem-labelled mononuclear cellsMantoux test then MRI scanning before and after administration of iron-labelled cells obtained by venesection.
Mantoux, Apheresis, Labelled cellsMantoux testMantoux test then MRI scanning before and after administration of iron-labelled cells obtained by apheresis.
Mantoux, Apheresis, Labelled cellsAutologous Endorem-labelled mononuclear cellsMantoux test then MRI scanning before and after administration of iron-labelled cells obtained by apheresis.
Mantoux, Administration of EndoremMantoux testMantoux test then MRI scanning before and after administration of Endorem.
Administration of Intra-dermal SPIOAdministration of intra-dermal EndoremMRI scanning before and after intra-dermal injection of SPIO.
Mantoux, Administration of EndoremAdministration of EndoremMantoux test then MRI scanning before and after administration of Endorem.
Mantoux onlyMantoux testMantoux test then serial MRI scanning.
Primary Outcome Measures
NameTimeMethod
Change in signal intensity in the region of interest on MRI scanning0 hours, 24 hours, 48 hours, 3 - 5 days
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University of Edinburgh / Royal Infirmary of Edinburgh

🇬🇧

Edinburgh, Scotland, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath